Jobs
-
Mast Therapeutics says that top-line results from a Phase 2a study of its AIR001 sodium nitrite inhalation solution for the treatment of heart failure with preserved ejection fraction (HFpEF) demonstrated statistically significant change in pulmonary… Read more . . .
-
The FDA has approved Avanir Pharmaceuticals’ intranasal sumatriptan for the treatment of acute migraines, the company said. The product, which Avanir licensed from OptiNose in 2013, will be marketed in the US as Onzetra Xsail.… Read more . . .
-
Skyepharma has announced agreements with Sanofi and Mundipharma that will transfer Mexican, Central American, and South American development, licensing and marketing rights for the Flutiform fluticasone/formoterol MDI to Mundipharma. Sanofi will continue to manufacture Flutiform… Read more . . .
-
Milestone Pharmaceuticals has announced today that its MSP-2017 intranasal calcium channel antagonist has been assigned the unique non-proprietary name “etripamil” by the United States Adopted Name (USAN) Council. The company is developing the etripamil nasal… Read more . . .
-
Dutch intranasal vaccine developer Mucosis has received €3.7 million from the Wellcome Trust for clinical development of its SynGEM intranasal respiratory syncytial virus (RSV) vaccine, the company said. The money will be used to fund… Read more . . .
-
MannKind Corporation has announced an agreement to develop “multiple inhaled therapeutic products” with a company called Receptor Life Sciences, described as a “newly formed entity.” MannKind says that Receptor will license MannKind’s manufacturing technology and… Read more . . .
-
Neurelis says that it has received guidance from the FDA regarding clinical trial requirements for the company’s NRL-1 intranasal diazepam for the treatment of acute repetitive seizures in epilepsy patients and is now initiating the… Read more . . .
-
Turing Pharmaceuticals said that it has received a no objection letter from Health Canada regarding the initiation of Phase 1 trials of TUR-002 intranasal ketamine for the reduction of suicidal ideations and that it expects… Read more . . .
-
Acerus Pharmaceuticals has received approval from Health Canada to market Natesto nasal gel as a testosterone replacement therapy in adult males with hypogonadism, and the product should be available in Canada by mid-2016, the company… Read more . . .
-
Mylan submitted an abbreviated new drug application (ANDA) to the FDA for its fluticasone propionate/salmeterol DPI, a generic version of GSK’s Advair Diskus, for the treatment of asthma and COPD in December 2015, the company… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA